PROCEPT investors cite handpiece sales disclosures in securities class action
Hagens Berman says a securities class action has been filed over PROCEPT BioRobotics’ handpiece sales disclosures and is seeking investors to help lead the case.
Hagens Berman says a securities class action has been filed against PROCEPT BioRobotics Corp. and other defendants over allegations that the company misled investors about U.S. handpiece sales tied to its Aquablation therapy business.
According to the investor alert, the complaint says the company used discounts to encourage bulk orders beyond customer procedure demand, which allegedly pulled sales forward and inflated reported unit sales and revenue.
What the complaint alleges
In the release, Hagens Berman says the proposed class covers investors who bought or otherwise acquired PROCEPT common stock between Feb. 28, 2024, and Feb. 25, 2026. The alert says the complaint alleges the company withheld information about its business, operations and financial condition.
The release points to three disclosures it says were important. On Aug. 6, 2025, PROCEPT reported second-quarter results and handpiece sales missed consensus estimates by a wide margin, according to the firm. On Nov. 4, 2025, the company again missed expected handpiece unit sales, and management said it was working on “optimization of field inventory” and had not been “managing customer inventory,” with some customers “probably carrying too much,” the alert says.
Then, on Feb. 25, 2026, PROCEPT reported fourth-quarter 2025 results and disclosed the actual number of procedures in the field, according to the release. Hagens Berman says the company stated that U.S. handpiece sales materially exceeded procedures in each quarter since the first quarter of 2023.
Background and context
The alert says cumulative excess customer inventory of handpieces was more than 10,000 units. It also says U.S. handpiece sales sequentially fell by 30%, and that PROCEPT said it was eliminating a previously undisclosed bulk-order discount program designed to encourage large purchases during “the final weeks” of each quarter.
By Feb. 25, 2026, PROCEPT shares had declined by $22.06, or more than 48%, compared with the Aug. 6, 2025 close, according to the release. Those figures are from the law firm’s investor alert, not an independent court filing summary.
What the firm said
Hagens Berman says it is investigating federal securities law claims and is asking investors with losses to contact the firm about serving as lead plaintiff. The release gives a lead plaintiff deadline of Sept. 22, 2026.
The alert quotes Hagens Berman partner Reed Kathrein as saying the firm is focused on whether PROCEPT intentionally pulled in sales from future quarters and whether its investor communications were transparent.
What happens next
Investors who believe they are part of the proposed class have until Sept. 22, 2026, to seek lead plaintiff status, according to the release. Hagens Berman provides contact information in its notice for interested investors.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.